SCHEMBL3985708

SCHEMBL3985708

CC(C)(C)OC(=O)N1CCN(C(=O)CC#N)CC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
ALDH1A1 P00352 2/20 0.55
MAPT P10636 2/20 0.55
USP2 O75604 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CTSK P43235 1/20 0.47
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
GPR119 Q8TDV5 3/20 0.44
KDM4E B2RXH2 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
DTYMK P23919 1/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
HPGD P15428 1/20 0.42
EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL434435 0.80 USP2 (0.53) MEN1KMT2AALDH1A1MAPTUSP2
SCHEMBL14417884 0.80 KDM4E (0.54) MEN1KMT2AALDH1A1MAPTUSP2
SCHEMBL18294 0.80 USP2 (0.69) MEN1KMT2AALDH1A1MAPTUSP2
SCHEMBL698803 0.80 USP2 (0.69) MEN1KMT2AALDH1A1MAPTUSP2
SCHEMBL8431612 0.79 SMN1; SMN2 (0.55) MEN1KMT2AALDH1A1MAPTUSP2
SCHEMBL1970198 0.79 USP2 (0.55) MEN1KMT2AALDH1A1MAPTUSP2
SCHEMBL1554780 0.78 MAPT (0.71) MEN1KMT2AALDH1A1MAPTUSP2
SCHEMBL4092828 0.78 ALDH1A1 (0.50) MEN1KMT2AALDH1A1MAPTUSP2
SCHEMBL15448148 0.77 ALDH1A1 (0.48) MEN1KMT2AALDH1A1MAPTUSP2
SCHEMBL908336 0.77 ALDH1A1 (0.62) MEN1KMT2AALDH1A1USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118754861-A Substituted alkynylene compounds as anticancer agents 奥里吉恩肿瘤学有限公司 2024-10-11 CN disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 WO disclosed
EP-3740473-A1 SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS Aurigene Discovery Technologies Limited (IN) 2020-11-25 EP disclosed
CN-111902403-A Substituted alkynylene compounds as anticancer agents 奥里吉恩发现科技有限公司 2020-11-06 CN disclosed
WO-2019142126-A1 SUBSTITUTED ALKYNYLENE COMPOUNDS AS ANTICANCER AGENTS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2019-07-25 WO disclosed
EP-2885285-B1 PYRAZOLE DRIVATIVES WHICH INHIBIT LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INT (DE) 2016-10-19 EP disclosed
US-9403830-B2 Inhibitors of leukotriene production BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-08-02 US disclosed
US-9403830-B2 Inhibitors of leukotriene production BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2016-08-02 US disclosed
US-9187487-B2 Azaindole derivatives as tyrosine kinase inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2015-11-17 US disclosed
WO-2012158785-A1 AZAINDOLE DERIVATIVES AS TYROSINE KINASE INHIBITORS PRINCIPIA BIOPHARMA INC. (US) 2012-11-22 WO disclosed
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 US disclosed
US-20080274075-A1 Poly(Ethylene Glycol) Derivatives and Process For Their Coupling to Proteins NOVO NORDISK HEALTHCARE A/G (CH) 2008-11-06 US disclosed
EP-1549613-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY Abbott Laboratories (US) 2005-07-06 EP disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 US disclosed
WO-2004033419-A1 SULFONAMIDES HAVING ANTIANGIOGENIC AND ANTICANCER ACTIVITY ABBOTT LABORATORIES (US) 2004-04-22 WO disclosed
EP-0574906-B1 Piperazine and homopiperazine derivatives, pharmaceutical compositions containing them and process for preparing the same NISSHIN FLOUR MILLING CO (JP) 2001-08-22 EP disclosed
US-5380724-A Inhibitors of lipid peroxidation GYOGYSZERKUTATO INTEZET KFT (HU) 1995-01-10 US disclosed
EP-0574906-A2 Piperazine and homopiperazine derivatives, pharmaceutical compositions containing them and process for preparing the same NISSHIN FLOUR MILLING CO., LTD. (JP) 1993-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP MEN1 580/4885KMT2A 647/4885ALDH1A1 3463/4885
US-20080274075-A1 Poly(Ethylene Glycol) Derivatives and Process For Their Coupling to Proteins RPS27A, MRPL21, PEBP1 MEN1 2678/4885KMT2A 4685/4885ALDH1A1 4568/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP MEN1 580/4885KMT2A 647/4885ALDH1A1 3463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.